- -

Basal plus basal-bolus approach in type 2 diabetes

RiuNet: Institutional repository of the Polithecnic University of Valencia

Share/Send to

Cited by


Basal plus basal-bolus approach in type 2 diabetes

Show full item record

Ampudia-Blasco, J.; Rossetti ., P.; Ascaso, JF. (2011). Basal plus basal-bolus approach in type 2 diabetes. Diabetes Technology & Therapeutics. 13:75-83. doi:10.1089/dia.2011.0001

Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10251/29638

Files in this item

Item Metadata

Title: Basal plus basal-bolus approach in type 2 diabetes
Author: Ampudia-Blasco, Javier Rossetti ., Paolo Ascaso, Juan F.
UPV Unit: Universitat Politècnica de València. Instituto Universitario de Automática e Informática Industrial - Institut Universitari d'Automàtica i Informàtica Industrial
Issued date:
[EN] Type 2 diabetes is characterized by insulin resistance and progressive b-cell deterioration. As b-cell function declines, most patients with type 2 diabetes treated with oral agents, in monotherapy or combination, ...[+]
Copyrigths: Reserva de todos los derechos
Diabetes Technology & Therapeutics. (issn: 1520-9156 )
DOI: 10.1089/dia.2011.0001
Mary Ann Liebert
Publisher version: http://online.liebertpub.com/doi/pdf/10.1089/dia.2011.0001
Description: This is a copy of an article published in the Diabetes Technology and Therapeutics © 2011 [copyright Mary Ann Liebert, Inc.]; Diabetes Technology and Therapeutics is available online at: http://online.liebertpub.com.
F.J.A.-B. has received honoraria as speaker and/or consultant from Abbott, AstraZeneca, Bristol-Myers Squibb, Glaxo-SmithKline, LifeScan, Lilly, Madaus, MannKind Corp., Medtronic, Menarini, Merch Farma y Quimica, SA, MSD, ...[+]
Type: Artículo



This item appears in the following Collection(s)

Show full item record